Ingalls & Snyder LLC Supernus Pharmaceuticals, Inc. Transaction History

Ingalls & Snyder LLC

$2.56 Billion
Q3 2024

A detailed history of Ingalls & Snyder LLC transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Ingalls & Snyder LLC holds 11,500 shares of SUPN stock, worth $416,530. This represents 0.01% of its overall portfolio holdings.

Number of Shares

11,500

Previous 21,688 46.98%

Holding current value

$416,530

Previous $580,000 38.1%

% of portfolio

0.01%

Previous 0.02%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$25.77 - $35.16 $262,544 - $358,210	-10,188 Reduced 46.98%	11,500 $359,000
Q2 2024 Jul 31, 2024	SELL	$25.99 - $33.85 $25,990 - $33,850	-1,000 Reduced 4.41%	21,688 $580,000
Q4 2023 Jan 29, 2024	SELL	$22.72 - $29.68 $45,440 - $59,360	-2,000 Reduced 8.1%	22,688 $657,000
Q3 2023 Nov 02, 2023	SELL	$27.57 - $32.91 $314,298 - $375,173	-11,400 Reduced 31.59%	24,688 $681,000
Q2 2023 Jul 27, 2023	SELL	$29.91 - $38.73 $2,991 - $3,872	-100 Reduced 0.28%	36,088 $1.09 Million
Q1 2023 May 09, 2023	SELL	$34.93 - $42.03 $139,720 - $168,120	-4,000 Reduced 9.95%	36,188 $1.31 Million
Q4 2021 Feb 11, 2022	SELL	$26.37 - $34.22 $785,826 - $1.02 Million	-29,800 Reduced 42.58%	40,188 $1.17 Million
Q3 2021 Oct 27, 2021	SELL	$23.54 - $31.39 $54,142 - $72,197	-2,300 Reduced 3.18%	69,988 $1.87 Million
Q4 2020 Jan 27, 2021	BUY	$17.7 - $25.81 $15,930 - $23,229	900 Added 1.26%	72,288 $1.82 Million
Q3 2020 Oct 21, 2020	BUY	$20.2 - $25.05 $4,040 - $5,010	200 Added 0.28%	71,388 $1.49 Million
Q2 2020 Jul 31, 2020	BUY	$17.09 - $24.89 $8,545 - $12,445	500 Added 0.71%	71,188 $1.69 Million
Q4 2019 Jan 15, 2020	SELL	$19.93 - $29.13 $2.08 Million - $3.04 Million	-104,200 Reduced 59.58%	70,688 $1.68 Million
Q3 2019 Oct 16, 2019	BUY	$25.47 - $33.37 $249,606 - $327,026	9,800 Added 5.94%	174,888 $4.81 Million
Q2 2019 Jul 11, 2019	SELL	$29.96 - $38.87 $164,780 - $213,785	-5,500 Reduced 3.22%	165,088 $5.46 Million
Q1 2019 Apr 11, 2019	SELL	$32.77 - $41.99 $16,385 - $20,995	-500 Reduced 0.29%	170,588 $5.98 Million
Q4 2018 Jan 24, 2019	SELL	$30.84 - $49.51 $3,084 - $4,951	-100 Reduced 0.06%	171,088 $5.68 Million
Q2 2018 Aug 10, 2018	SELL	$44.1 - $59.85 $103,502 - $140,467	-2,347 Reduced 1.35%	171,188 $10.2 Million
Q1 2018 Apr 17, 2018	SELL	$37.15 - $46.9 $74,300 - $93,800	-2,000 Reduced 1.14%	173,535 $7.95 Million
Q4 2017 Jan 19, 2018	SELL	$36.4 - $42.6 $3,640 - $4,260	-100 Reduced 0.06%	175,535 $7 Million
Q3 2017 Oct 20, 2017	BUY	$36.75 - $49.65 $6.45 Million - $8.72 Million	175,635	175,635 $7.03 Million

Others Institutions Holding SUPN

# of Institutions

282

Shares Held

60.9M

Call Options Held

27.7K

Put Options Held

11.3K

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.94B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ingalls & Snyder LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ingalls & Snyder LLC with notifications on news.

Account

Ingalls & Snyder LLC Supernus Pharmaceuticals, Inc. Transaction History